A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
Active, not recruiting · Phase 1, Phase 2 · NCT04077099
Conditions: NSCLC
At a glance
- Research payments reported, 2025
- $86,778
- U.S. investigators named
- 8
- Sites paid
- 8
- Planned or actual enrollment
- 95
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- REGN5093 (drug)
- Dates
- Started 2020-01-07; completion 2027-07-06
- Results posted
- Not yet
This study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer (NSCLC) with MET alteration. The main purpose of this study is to determine the safety, tolerability, and effectiveness of REGN5093. The study has two phases. The main goal of Phase 1 is to determine a safe dose(s) of REGN5093. The main goal of phase 2 of the study is to use the REGN5093 drug dose(s) found in Phase 1 to see how well REGN5093 works to shrink tumors. The study is looking at several other research questions, including: * Side effects that may be experienced by people taking REGN5093 * How REGN5093 works in the body * How much REGN5093 is present in the blood * To see if REGN5093 works to reduce…
From ClinicalTrials.gov, last updated 2026-09-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $86,778 in research payments for this study in 2025 (38 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Sai-hong I Ou, MD Hematology & Oncology · Orange, CA
- Chul Kim Hematology & Oncology · Washington, DC
- Jhanelle Gray, MD Internal Medicine · Tampa, FL
- Mark M. Awad, MD, PHD Medical Oncology · New York, NY
- Alexander Edward D. Drilon, MD Medical Oncology · New York, NY
- Jorge E. Gomez, MD Medical Oncology · New York, NY
- Liza C. Villaruz, M.D. Internal Medicine · Pittsburgh, PA
- George R. Blumenschein JR., M.D. Medical Oncology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Georgetown University $26,108
- Memorial Sloan Kettering Cancer Center $22,066
- Mount Sinai School of Medicine $16,349
- Ut MD Anderson Cancer Center $6,497
- Moffitt Cancer Center $4,474
- University of Pittsburgh Cancer Institute Cancer Services $3,982
- $3,653
- Dana Farber Mass General Brigham Cancer Care Inc $2,129
- Uci Health-Orange, CA $1,519
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.